Dolby Laboratories · NYSE:DLB
Dolby Laboratories — Q2 2026 Earnings Presentation
9 slides from Dolby Laboratories's earnings presentation, Apr 30, 2026
Slide 1: Dolby Laboratories Reports Second Quarter 2026 Financial Results
NEWS RELEASE Dolby Laboratories Reports Second Quarter 2026 Financial Results 2026-04-30 SAN FRANCISCO, April 30, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB) today announced the company's nancial results for the second quarter of scal 2026. "We continue to strengthen our position and c
Slide 2: Dividend and Financial Outlook
Hisense, TCL and Philips have announced plans to release a wide range of Dolby Vision 2 enabled TVs globally by the end of the year, with Peacock and Canal+ committed to delivering content. Sharp and SK Planet joined the Video Distribution Program, bringing the licensor total to 40. Dividend Today,
Slide 3: Conference Call Information and Non-GAAP Financial Information
non-GAAP basis. E ective tax rate is anticipated to be around 23% on a GAAP basis and around 20% on a non-GAAP basis. Diluted earnings per share is anticipated to range from $2.66 to $2.81 on a GAAP basis and from $4.30 to $4.45 on a non-GAAP basis. Conference Call Information Members of Dolby manag
Slide 4: Forward-Looking Statements
relate to costs associated with exit or disposal activities, employee severance bene ts, and asset impairments. Dolby excludes restructuring costs, including any adjustments to charges recorded in prior periods (which may be credits), as Dolby believes that these costs are not representative of its
Slide 5: About Dolby
electronics, PC, and other markets; the loss of, or reduction in sales by, a key customer, partner, or licensee; pricing pressures; risks relating to changing trends in the way that content is distributed and consumed; risks relating to conducting business internationally, including trade restrictio
Slide 6: Condensed Consolidated Statements of Operations
Gross profit 350,899 333,724 654,397 649,949 Operating expenses: Research and development 63,651 61,707 132,728 128,345 Sales and marketing 96,163 89,629 187,715 184,028 General and administrative 75,955 70,415 146,198 140,507 Restructuring charges 2,184 4,210 12,650 9,426 Total operating expenses 2
Slide 7: Interim Condensed Consolidated Statements of Cash Flows
DOLBY LABORATORIES, INC. INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands; unaudited) Fiscal Year-To-Date Ended March 27, March 28, 2026 2025 Operating activities: Net income including noncontrolling interest $ 149,135 $ 160,296 Adjustments to reconcile net income to net cash pr
Slide 8: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations (unaudited) The following tables present Dolby's GAAP financial measures reconciled to the non-GAAP financial measures included in this release for the second quarters of fiscal 2026 and fiscal 2025: Net income: Fiscal Quarter Ended March 27, March 28, (in thousands)
Slide 9: Investor Contact and Media Contact
Non-GAAP diluted earnings per share (low - high end of range) $ 0.56 $ 0.71 $ 4.30 $ 4.45 Weighted-average shares outstanding - diluted (in thousands) 95,000 95,000 95,700 95,700 Investor Contact: Peter Goldmacher 415-254-7415 peter.goldmacher@dolby.com Media Contact: media@dolby.com View original c